Hoffmann-La Roche Inc.;VIB vzw;Life Sciences Research Partners vzw
发明人:
Sanne Lysbet de Haas,Paul Delmar,Diether Lambrechts,Stefan Scherer
申请号：
US14191051
公开号：
US20140294811A1
申请日:
2014.02.26
申请国别(地区):
US
年份:
2014
代理人:
摘要：
The invention is concerned with a method of predicting a patient's susceptibility to developing hypertension associated with an anti-angiogenesis treatment, such as bevacizumab, by determining the genotype of KDR gene and/or EGF gene. The invention further relates to a pharmaceutical composition comprising an angiogenesis inhibitor, such as bevacizumab, for the treatment of a patient suffering from cancer based on the genotype of KDR gene and/or EGF. The invention further relates to a method for reducing the risk of hypertension associated with an anti-angiogenesis therapy, such as bevacizumab, in a patient suffering from cancer by determining the genotype of KDR gene and/or EGF gene.
